Is Sms Pharmaceuticals a good stock to invest in?

Sms Pharmaceuticals can be analyzed on the following key metrics - TTM P/E: 26.04 Sector P/E: 22.67 Dividend Yield: 0.16% D/E ratio: -

Sms Pharmaceuticals Share Price

Sector: Biotechnology & Drugs

Powered by

248.55 +1.80 (0.73%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 248.05

Today’s High 252.10

52 Week Low 175.00

52 Week High 398.00

Key Metrics

Market Cap (In Cr) 2199.77
Beta 1.39
Div. Yield (%) 0.16
P/B 3.43
TTM P/E 26.04
Peg Ratio 8.55
Sector P/E 22.67
D/E 0
Open Price 251.95
Prev Close 246.75

View All Metrics

Sms Pharmaceuticals Analysis

Price Analysis

1 Week

9.07%
3 Months

18.14%
6 Month

7.32%
YTD

3.71%
1 Year

9.55%

Risk Meter

52% Low risk
52% Moderate risk
52% Balanced Risk
52% High risk
52% Extreme risk

Sms Pharmaceuticals News

Dangerous waters: A Swedish study found supposedly treated waste water in the Patancheru lake (above) had 21 active drug ingredients. Mahesh Kumar A / AP

Premium

Drug pollution: Andhra under pressure to act

3 min read . 03 Feb 2009

View More News

Sms Pharmaceuticals Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2025

Total Revenue
782.75

Selling/ General/ Admin Expenses Total
80.08

Depreciation/ Amortization
34.34

Other Operating Expenses Total
40.26

Total Operating Expense
678.09

Operating Income
104.65

Net Income Before Taxes
92.34

Net Income
69.14

Diluted Normalized EPS
8.16

Period
2024

Total Revenue
709.26

Selling/ General/ Admin Expenses Total
111.93

Depreciation/ Amortization
31.52

Total Operating Expense
624.15

Operating Income
85.11

Net Income Before Taxes
66.11

Net Income
49.83

Diluted Normalized EPS
5.88

Period
2023

Total Revenue
522.05

Selling/ General/ Admin Expenses Total
87.69

Depreciation/ Amortization
32.13

Total Operating Expense
499.6

Operating Income
22.45

Net Income Before Taxes
5.35

Net Income
-7.06

Diluted Normalized EPS
-0.83

Period
2022

Total Revenue
519.87

Selling/ General/ Admin Expenses Total
89.55

Depreciation/ Amortization
32.15

Total Operating Expense
437.69

Operating Income
82.18

Net Income Before Taxes
68.5

Net Income
62.22

Diluted Normalized EPS
7.35

Period
2021

Total Revenue
563.18

Selling/ General/ Admin Expenses Total
72

Depreciation/ Amortization
22.28

Total Operating Expense
464.34

Operating Income
98.84

Net Income Before Taxes
91.12

Net Income
62.53

Diluted Normalized EPS
7.39

Period
2020

Total Revenue
411.95

Selling/ General/ Admin Expenses Total
59.95

Depreciation/ Amortization
22.07

Total Operating Expense
354.04

Operating Income
57.9

Net Income Before Taxes
50.76

Net Income
31.57

Diluted Normalized EPS
3.73

Period
2019

Total Revenue
464.91

Selling/ General/ Admin Expenses Total
54.12

Depreciation/ Amortization
19.27

Total Operating Expense
394.09

Operating Income
70.83

Net Income Before Taxes
62.35

Net Income
40.05

Diluted Normalized EPS
4.73

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Sms Pharmaceuticals Technical

Moving Average SMA

5 Day232.45
10 Day241.86
20 Day248.98

50 Day246.46
100 Day225
300 Day256.67

Sms Pharmaceuticals Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Panacea Biotec
413.15
4.25
1.04
581
129.65
2544.4

Novartis India
1002.9
-7.95
-0.79
1248
744.95
2476.24

Sms Pharmaceuticals
248.55
1.8
0.73
398
175
2199.77

Amrutanjan Health Care
735.35
7.5
1.03
861.4
548.05
2140.7

Vimta Labs
438
-16.25
-3.58
591.5
233.25
1954.73

Sms Pharmaceuticals Shareholding

Shareholding Pattern

*Promoter pledging: 24.91%

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

30-May-25
Audited Results & Final Dividend

12-Feb-25
Quarterly Results & Others

08-Nov-24
Quarterly Results

05-Aug-24
Quarterly Results

29-May-24
Audited Results & Final Dividend

08-Feb-24
Quarterly Results & Preferential issue

08-Nov-23
Quarterly Results

08-Aug-23
Quarterly Results

24-May-23
Audited Results & Final Dividend

09-Feb-23
Quarterly Results

Meeting Date
Announced on
Purpose

30-Sept-24
05-Aug-24
AGM

06-Mar-24
13-Feb-24
EGM

30-Sept-23
08-Aug-23
AGM

12-Aug-23
11-Jul-23
POM

31-Mar-22
25-Feb-22
POM

Announced on
Record Date
Ex-Dividend
Dividend Value

30-May-25
-
-
0.4

29-May-24
23-Sept-24
23-Sept-24
0.4

24-May-23
22-Sept-23
22-Sept-23
0.3

30-May-22
23-Sept-22
22-Sept-22
0.3

28-May-21
-
22-Sept-21
0.3

View All

Company Profile

ABOUT Sms Pharmaceuticals

Industry Biotechnology & Drugs
ISIN INE812G01025
BSE Code 532815
NSE Code SMSPHARMA

SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic, and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel, lamotrigine, penciclovir, valaciclovir, and others. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.

MANAGEMENT

Ramesh Potluri Executive Chairman of the Board, Managing Director
Lakshmi Tammineedi Chief Financial Officer
Thirumalesh Tumma Chief Compliance Officer, Company Secretary
Vamsi Potluri Additional Director

SMS PHARMACEUTICALS SUMMARY

Sms Pharmaceuticals is trading 0.73% upper at Rs 248.55 as compared to its last closing price. Sms Pharmaceuticals has been trading in the price range of 252.10 & 248.05. Sms Pharmaceuticals has given 3.71% in this year & 9.07% in the last 5 days.

Sms Pharmaceuticals has TTM P/E ratio 26.04 as compared to the sector P/E of 22.67.

The company posted a net profit of 20.32 Crores in its last quarter.

Listed peers of Sms Pharmaceuticals include Panacea Biotec (1.04%), Novartis India (-0.79%), Sms Pharmaceuticals (0.73%) etc.

Sms Pharmaceuticals has a 66.26% promoter holding & 33.74% public holding.

FAQs about Sms Pharmaceuticals

Sms Pharmaceuticals is trading at 248.55 as on 27 Jun, 2025 3:28:25 PM. This is 0.73% upper as compared to its previous closing price of 246.75

The market capitalization of Sms Pharmaceuticals is 2199.77 Cr as on 27 Jun, 2025 3:28:25 PM.

The 52 wk high for Sms Pharmaceuticals is 398.00 whereas the 52 wk low is 175.00

Sms Pharmaceuticals can be analyzed on the following key metrics -

TTM P/E: 26.04
Sector P/E: 22.67
Dividend Yield: 0.16%
D/E ratio: -

Sms Pharmaceuticals reported a net profit of 69.14 Cr in 2025.

Sms Pharmaceuticals Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Sms Pharmaceuticals Share Price

Price Range

Price Range

Key Metrics

Sms Pharmaceuticals Analysis

Sms Pharmaceuticals News

Drug pollution: Andhra under pressure to act

Sms Pharmaceuticals Financials

Forecast

Forecast

Forecast

Sms Pharmaceuticals Technical

Sms Pharmaceuticals Peers

Sms Pharmaceuticals Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Sms Pharmaceuticals

MANAGEMENT

SMS PHARMACEUTICALS SUMMARY

FAQs about Sms Pharmaceuticals

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue